Test Summary

Point mutation of the KIT oncogene at codon 816 (D816V) is seen in >90% of systemic mastocytosis (SM) cases. The presence of KIT D816V mutation is one of the minor criteria for diagnosis of SM and mutation testing can assist in diagnosis, particularly in limited specimens. KIT D816 mutations, including D816V, D816H and D816Y, are also the most common KIT mutations seen in the core-binding factor acute myeloid leukemia (AML). In both t(8;21) and inv(16)/t(16;16) AML, cases with KIT D816 mutation are associated with worse outcomes than unmutated cases.
This PCR-based DNA pyrosequencing assay sensitively detects the KIT D816V mutation down to 2%. If KIT mutation testing of gastrointestinal stromal tumor (GIST) or melanoma is needed, test code 19961 should be used instead, which tests for exons 8, 9, 11, 13 and 17 of the KIT gene by Sanger sequencing.

Aliases

Specimen Collection

Special Instructions

Preferred Specimen

Minimum Volume

Instructions

Patient Preparation

Storage

Transport Temperature

Specimen Stability

Limitations

Other Acceptable Specimens

Unacceptable Specimens

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Department

Reference Range

Setup Schedule / Expected Turnaround Time